Braveheart Bio Launches with $185 Million Series A, Appoints Biogen CEO Christopher Viehbacher as Chair
Braveheart Bio, a late clinical-stage biotechnology company focused on novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions, launched with $185 million in Series A funding led by investors including Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences2.
The company aims to advance its investigational cardiac myosin inhibitor, BHB-1893, which has potential to be a best-in-class treatment for HCM2.
Christopher Viehbacher, CEO of Biogen and former CEO of Sanofi, is appointed as Chair of Braveheart Bio’s Board of Directors2.
Braveheart Bio's leadership team includes Travis Murdoch, MD (President and CEO), Michele Anderson (Chief Development Officer), Paul Rickey (CFO), Marc Evanchik (SVP Pharmacology and Translational Medicine), and Natalie Dement (Head of Legal)2.
The company recently secured ex-China rights to Jiangsu Hengrui Pharmaceuticals’ selective myosin inhibitor HRS-1893 (branded as BHB-1893) for $65 million upfront in a deal that could exceed $1 billion, positioning itself as a competitor to Bristol Myers Squibb and Cytokinetics in the HCM space4.
Chris Viehbacher’s role as Chair provides Braveheart with leadership experience in both global pharma operations and innovation-focused biotech strategy, signaling strong guidance for the company's plans to advance late-stage cardiovascular therapies2.
Sources:
2. https://www.prnewswire.com/news-releases/braveheart-bio-launches-with-185m-series-a-aiming-to-transform-care-of-hypertrophic-cardiomyopathy-302604764.html